

# 5 | Else.

PATENT 10/29/02

Docket No.: 0708-4057

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

Applicants

Phyllis SHAPIRO

OCT 2 8 2002

Serial No.

09/865,759

Art Unit: 1631

TECH CENTER 1600/2900

Filed

May 25, 2001

Examiner: Carolyn L. Smith

For

Automated Method for Correcting Blood Analysis Parameter

Results Affected by Interference from Exogenous Blood

Substitutes in Whole Blood, Plasma and Serum

Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO THE SEPTEMBER 26, 2002 PTO COMMUNICATION

Dear Sir:

This Response is submitted in reply to the September 26, 2002 PTO communication received in the above-identified patent application and addresses the species election requirement for all claims.

## **REMARKS**

In the PTO communication dated September 26, 2002, the Examiner has set forth a restriction under 35 U.S.C. §121 in which the pending claims have been deemed to be directed to five patentably distinct species A-E, which relate to types of hemoglobin. To provide a complete response to the Examiner's restriction, applicants elect Species A, which is directed to a recombinant human hemoglobin. Further in